Post-Market Surveillance

A data-driven analysis of FDA medical device warning letter trends from 2024 through early 2026, covering the most common violations (CAPA, design controls, complaint handling), QMSR enforcement shifts since February 2026, notable enforcement actions against Beta Bionics, Abbott, Medline, and Philips, and practical compliance strategies for medical device manufacturers.

How to build and operate a quality management system for depot repair of reusable medical device capital equipment — receiving and triage, decontamination and biohazard protocols, diagnostic testing, repair and rework controls, calibration traceability, nonconformance handling, return-to-service release criteria, documentation requirements under FDA QMSR and ISO 13485, and audit readiness for depot service facilities.

How to determine whether your medical device maintenance, repair, or modification activity is FDA-defined servicing or remanufacturing — the 6 guiding principles from the May 2024 final guidance, the decision flowchart, automatically-classified activities, software change rules, documentation requirements, and regulatory exposure for OEMs, third-party servicers, and hospital HTM teams.

How to build a complete traceability system for field service on software-enabled medical devices — electronic service records, software version and configuration tracking, firmware update logs, audit trail requirements under 21 CFR Part 11, traceability for installed base management, complaint-to-service-record linkage, and FDA inspection readiness under QMSR and ISO 13485 Clause 7.5.9.

How to establish and justify preventive maintenance and calibration intervals for medical devices — manufacturer recommendations vs. risk-based alternative approaches, statistical methods for interval optimization, reliability-centered maintenance for healthcare, Joint Commission EC.02.04.01 and AEM program requirements, AAMI EQ56 guidance, ISO 13485 Clause 7.5.1 and Clause 7.5.6, FDA 21 CFR Part 820 calibration requirements, and documentation for audit readiness.

Step-by-step guide to building a dual PMSR/PSUR reporting architecture that satisfies both EU MDR/IVDR and Great Britain SI 2024/1368 requirements — data-period alignment, GB-specific content, MHRA standardized format, FSCA linkage, trend reporting, record retention, and responsible-owner mapping.

A practical guide to implementing MDR Article 88 trend reporting — covering denominator selection, expected frequency calculation, statistical significance testing, severity escalation, complaint coding, CAPA linkage, PSUR/PMSR integration, and the MDCG 2025 draft Q&A requirements.

How to design and implement a drift monitoring protocol for AI-enabled imaging devices under FDA PCCP — dataset shift, scanner drift, demographic drift, performance thresholds, monitoring cadence, retraining triggers, labeling changes, and when FDA submission is still required.

How to design a PMCF survey under EU MDR that Notified Bodies accept as Level 4 clinical evidence — sample frame construction, inclusion/exclusion criteria, endpoint mapping to CER claims, acceptance criteria, statistical power, bias controls, adverse event capture, and when surveys alone are insufficient.

Operational playbook for medical device PSIRT teams — SBOM component matching, exploitability analysis, VEX justification authoring, PSIRT severity scoring, CAPA trigger thresholds, field safety corrective action decisions, and customer communication timing.

Practical guide for building a coordinated vulnerability disclosure (CVD) program for medical devices — covering PSIRT setup, vulnerability intake and triage, CVSS scoring, SBOM linkage, field safety notices, FDA Section 524B requirements, EU expectations, and customer communication templates.

Data-driven analysis of medical device recall trends through 2024–2026 — 1,059 recall events, Class I recalls at a 15-year high, device failure as the new #1 cause, ~440 million units affected (up 55%), software defect trends, FDA early alert pilot, and risk mitigation strategies for manufacturers.

How to prepare, structure, and submit a compliant PSUR under MDR Article 86 — frequency by device class, MDCG 2022-21 template walkthrough, EUDAMED submission for Class III and implantables, benefit-risk analysis, PMS data integration, and the 2025 simplification proposal that may change reporting cadence.

How to prepare, validate, and publish the Summary of Safety and Clinical Performance (SSCP) under EU MDR Article 32 — MDCG 2019-9 Rev.1 template walkthrough, HCP and layperson sections, readability testing, Notified Body validation process, translation requirements, EUDAMED upload timelines, and common NB findings in 2026.

Complete guide to post-market surveillance and vigilance requirements for medical devices across MENA — SFDA MDS-REQ11 (2-day/10-day/30-day reporting, change notifications, 90-day renewal), UAE EDE biennial PSUR for high-risk devices, Turkey TITCK 6-month shortage notification, Israel IRH periodic post-marketing reports, and Egypt EDA vigilance obligations.

A complete guide to Field Safety Corrective Actions under EU MDR — when an FSCA is required, reporting timelines (2/10/15 days), how to prepare a Field Safety Notice (FSN), competent authority notification, EUDAMED integration, and how FSCA differs from FDA recalls.

A complete guide to medical device complaint handling — regulatory requirements under FDA 21 CFR 820 (QMSR), ISO 13485, and EU MDR, step-by-step process, MDR reportability decisions, CAPA integration, and documentation best practices.

Role-by-role action playbook for the May 28, 2026 EUDAMED mandatory deadline — covering actor registration, UDI/device registration, certificate uploads, and market surveillance obligations with a countdown checklist and member-state penalty matrix.

Learn how to respond to FDA Form 483 observations and Warning Letters for medical devices. Covers 2025-2026 enforcement statistics, top violations, response strategies, and the March 2026 draft guidance on 483 responses.

Comprehensive guide to FDA medical device recalls — voluntary vs mandatory recalls, Class I/II/III classification, corrections and removals under 21 CFR 806, reporting requirements, recall strategy, health hazard evaluation, and compliance best practices.